title: Overexpression of the RD RNA binding protein in hepatitis C virus-related             hepatocellular carcinoma.
abstract: Hepatocellular carcinoma (HCC) often exhibits a poor prognosis due to metastatic             spread caused by portal vein invasion (PVI). In the present study, we attempted             to identify a novel therapeutic target related to PVI of HCC. Based on pooled             genomic data, we identified RD RNA binding protein (RDBP), a member of the negative             elongation factor (NELF) transcription elongation regulatory complex, to be preferentially             overexpressed in HCC with PVI. We used quantitative reverse transcription polymerase             chain reaction (RT-PCR) and immuno-histochemical analyses to investigate the relationship             between RDBP mRNA and protein with metastatic potential in sample sets of hepatitis             C virus (HCV)-related HCC and corresponding non-HCC liver tissues. We also used             the small interfering RNA technique to examine the role of RDBP in invasion and             proliferation of HCC cells in vitro. Our data showed that both mRNA and protein             levels of RDBP were significantly higher in HCC compared to non-HCC liver tissue,             and that these levels were also significantly higher in HCC with PVI compared             to HCC without PVI. Multivariate analysis revealed that RDBP protein levels were             an independent risk factor for early intrahepatic recurrence of HCC within 2 years             of surgery. Knockdown of RDBP protein significantly inhibited the proliferation             and invasion of cells in vitro. These data demonstrate that RDBP is related to             the metastatic potential of HCC, suggesting a possible candidate for prevention             of HCC cell metastasis.
authors.affiliation: Department of Digestive Surgery and Surgical Oncology, Yamaguchi                     University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
authors.forename: Michihisa
authors.initials: M
authors.lastname: Iida
authors.forename: Norio
authors.initials: N
authors.lastname: Iizuka
authors.forename: Ryouichi
authors.initials: R
authors.lastname: Tsunedomi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tsutsui
authors.forename: Shin
authors.initials: S
authors.lastname: Yoshida
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Maeda
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Tokuhisa
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Sakamoto
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Yoshimura
authors.forename: Takao
authors.initials: T
authors.lastname: Tamesa
authors.forename: Masaaki
authors.initials: M
authors.lastname: Oka
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology / Q000821:virology*; D045744:Cell Line, Tumor; D019698:Hepatitis C, Chronic / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology / Q000821:virology*; D011169:Portal Vein / Q000473:pathology; D011379:Prognosis; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics; D014157:Transcription Factors / Q000096:biosynthesis* / Q000235:genetics; D014162:Transfection
chemical_list: D012333:RNA, Messenger; D034741:RNA, Small Interfering; D014157:Transcription Factors; C118437:negative elongation factor